Previous 10 | Next 10 |
Evelo Biosciences, Inc. (EVLO) Q4 2019 Earnings Conference Call February 13, 2020, 08:30 ET Company Participants Jessica Cotrone - VP & Head, Communications Balkrishan Gill - President, CEO & Director Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific ...
Evelo Biosciences (NASDAQ: EVLO ): Q4 GAAP EPS of -$0.70 misses by $0.09 . More news on: Evelo Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
—Strong 2019 marked by clinical data that validates platform— —Lead inflammation candidate EDP1815 showed positive clinical data across two separate cohorts— —EDP1815 Phase 2 study initiation expected in Q2 2020— —Multiple clinical readouts a...
Gainers: AIM ImmunoTech (NYSEMKT: AIM ) +44% . More news on: AIM ImmunoTech Inc., NeuroBo Pharmaceuticals, Inc., AquaBounty Technologies, Inc., Stocks on the move, , Read more ...
CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on ...
Gainers: OpGen (NASDAQ: OPGN ) +49% . More news on: OpGen, Inc., Insmed Incorporated, Artelo Biosciences, Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Evelo Biosciences ( EVLO +7.1% ) is up on 60% higher volume, a modest 88K shares, in reaction to its update on lead candidate EDP1815. More news on: Evelo Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
-- EDP1815 Phase 2 Interim Data in Psoriasis Expected by Year-End 2020 -- CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, toda...
CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...
CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres t...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...